Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank 指定難病告示番号
1 IL31RA 1件: JAK-STAT signaling pathway D11080 Nemolizumab 1件: 51
2 CSF2 8件: JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Shigellosis, Kaposi sarcoma-associated herpesvirus infection, Transcriptional misregulation in cancer, Rheumatoid arthritis D11343 Otilimab 1件: 46
3 CSF2RA 2件: JAK-STAT signaling pathway, Pathways in cancer D05066 Molgramostim 3件: 97, 229, 299
4 CSF2RA 2件: JAK-STAT signaling pathway, Pathways in cancer D05712 Regramostim 1件: 229
5 CSF2RA 2件: JAK-STAT signaling pathway, Pathways in cancer D05803 Sargramostim 7件: 6, 28, 60, 62, 96, 229, 285
6 CSF2RA 2件: JAK-STAT signaling pathway, Pathways in cancer D09930 Mavrilimumab 2件: 41, 46
7 CSF3R 3件: PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Pathways in cancer D03235 Filgrastim 35件: 2, 6, 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331
8 CSF3R 3件: PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Pathways in cancer D03247 Lenograstim 7件: 2, 13, 16, 18, 19, 57, 65
9 CSF3R 3件: PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Pathways in cancer D06889 Pegfilgrastim 1件: 60
10 EGFR 19件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Shigellosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D01977 Gefitinib 1件: 75
11 EGFR 19件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Shigellosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D03455 Cetuximab 2件: 51, 86
12 EGFR 19件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Shigellosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D07907 Erlotinib 1件: 94
13 EGFR 19件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Shigellosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D08108 Lapatinib 3件: 34, 74, 75
14 EGFR 19件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Shigellosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D08950 Neratinib 1件: 34
15 EGFR 19件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Shigellosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D11251 Icotinib 1件: 34
16 EGFR 19件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Shigellosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D11772 Tesevatinib 1件: 67
17 EPOR 3件: PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Pathways in cancer D09946 Peginesatide 1件: 283
18 MTOR 21件: Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D00753 Sirolimus 40件: 2, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 53, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 300, 331
19 MTOR 21件: Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D02714 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277
20 MTOR 21件: Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D06068 Temsirolimus 1件: 13
21 GHR 3件: Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway D03297 Mecasermin 6件: 65, 78, 96, 168, 265, 299
22 GHR 3件: Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway D05394 Pegvisomant 2件: 78, 265
23 GHR 3件: Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway D11193 Somavaratan 1件: 78
24 GHR 3件: Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway D11194 Somapacitan 2件: 78, 195
25 GHR 3件: Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway D11486 Lonapegsomatropin 1件: 78
26 IFNA1 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab 1件: 49
27 IFNA1 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab 1件: 49
28 IFNA2 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab 1件: 49
29 IFNA2 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab 1件: 49
30 IFNA4 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab 1件: 49
31 IFNA4 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab 1件: 49
32 IFNA5 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab 1件: 49
33 IFNA5 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab 1件: 49
34 IFNA6 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab 1件: 49
35 IFNA6 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab 1件: 49
36 IFNA7 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab 1件: 49
37 IFNA7 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab 1件: 49
38 IFNA8 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab 1件: 49
39 IFNA8 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab 1件: 49
40 IFNA10 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab 1件: 49
41 IFNA10 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab 1件: 49
42 IFNA13 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab 1件: 49
43 IFNA13 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab 1件: 49
44 IFNA14 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab 1件: 49
45 IFNA14 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab 1件: 49
46 IFNA16 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab 1件: 49
47 IFNA16 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab 1件: 49
48 IFNA17 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab 1件: 49
49 IFNA17 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab 1件: 49
50 IFNA21 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09662 Rontalizumab 1件: 49
51 IFNA21 12件: PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Lipid and atherosclerosis D09668 Sifalimumab 1件: 49
52 IFNAR1 10件: PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D00745 Interferon alfa-2a 1件: 56
53 IFNAR1 10件: PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D00746 Interferon beta-1b 1件: 13
54 IFNAR1 10件: PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D02745 Interferon alfa-2b 2件: 25, 34
55 IFNAR1 10件: PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D03305 Interferon alfa 6件: 13, 25, 26, 28, 56, 96
56 IFNAR1 10件: PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D04554 Interferon beta-1a 4件: 13, 26, 96, 97
57 IFNAR1 10件: PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D10483 Peginterferon beta-1a 1件: 13
58 IFNAR1 10件: PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D11082 Anifrolumab 3件: 46, 49, 53
59 IFNAR2 10件: PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D00745 Interferon alfa-2a 1件: 56
60 IFNAR2 10件: PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D00746 Interferon beta-1b 1件: 13
61 IFNAR2 10件: PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D02745 Interferon alfa-2b 2件: 25, 34
62 IFNAR2 10件: PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D03305 Interferon alfa 6件: 13, 25, 26, 28, 56, 96
63 IFNAR2 10件: PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D04554 Interferon beta-1a 4件: 13, 26, 96, 97
64 IFNAR2 10件: PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D10483 Peginterferon beta-1a 1件: 13
65 IFNAR2 10件: PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer D11082 Anifrolumab 3件: 46, 49, 53
66 IFNG 18件: Proteasome, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D04242 Fontolizumab 1件: 46
67 IFNG 18件: Proteasome, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Systemic lupus erythematosus, Rheumatoid arthritis D11120 Emapalumab 3件: 49, 65, 107
68 IFNGR1 12件: Necroptosis, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D00747 Interferon gamma-1b 7件: 18, 65, 85, 228, 299, 301, 326
69 IFNGR2 11件: Necroptosis, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D00747 Interferon gamma-1b 7件: 18, 65, 85, 228, 299, 301, 326
70 IL2RA 7件: Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer D00748 Aldesleukin 6件: 2, 35, 49, 65, 96, 97
71 IL2RA 7件: Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer D03058 Basiliximab 6件: 2, 50, 66, 97, 222, 228
72 IL2RA 7件: Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer D03639 Daclizumab 8件: 13, 56, 60, 65, 97, 107, 283, 284
73 IL2RB 8件: Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer, Transcriptional misregulation in cancer D00748 Aldesleukin 6件: 2, 35, 49, 65, 96, 97
74 IL2RG 8件: Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer, Primary immunodeficiency D00748 Aldesleukin 6件: 2, 35, 49, 65, 96, 97
75 IL4 7件: PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Leishmaniasis, Pathways in cancer D03117 Binetrakin 1件: 46
76 IL4R 5件: PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Pathways in cancer D10354 Dupilumab 5件: 51, 97, 98, 160, 162
77 IL5 4件: JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, T cell receptor signaling pathway, Pathways in cancer D04923 Mepolizumab 4件: 44, 45, 98, 162
78 IL5 4件: JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, T cell receptor signaling pathway, Pathways in cancer D08985 Reslizumab 2件: 44, 98
79 IL5RA 2件: JAK-STAT signaling pathway, Pathways in cancer D09874 Benralizumab 5件: 44, 45, 98, 162, 299
80 IL6 23件: Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis, Lipid and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
81 IL6 23件: Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis, Lipid and atherosclerosis D08976 Pomalidomide 5件: 28, 51, 85, 227, 331
82 IL6 23件: Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis, Lipid and atherosclerosis D09669 Siltuximab 2件: 28, 331
83 IL6 23件: Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis, Lipid and atherosclerosis D10080 Sirukumab 2件: 41, 46
84 IL6 23件: Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Malaria, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis, Lipid and atherosclerosis D12487 Olokizumab 2件: 46, 96
85 IL6R 6件: Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Non-alcoholic fatty liver disease, Pathways in cancer D02596 Tocilizumab 21件: 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331
86 IL6R 6件: Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Non-alcoholic fatty liver disease, Pathways in cancer D10161 Sarilumab 5件: 41, 46, 84, 107, 271
87 IL6R 6件: Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Non-alcoholic fatty liver disease, Pathways in cancer D11079 Satralizumab 3件: 11, 13, 86
88 IL10 11件: Viral protein interaction with cytokine and cytokine receptor, JAK-STAT signaling pathway, T cell receptor signaling pathway, Pertussis, Yersinia infection, Leishmaniasis, Malaria, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Systemic lupus erythematosus D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
89 IL11RA 1件: JAK-STAT signaling pathway D05266 Oprelvekin 2件: 96, 288
90 IL12A 14件: Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Malaria, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Lipid and atherosclerosis D09214 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
91 IL12B 14件: Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Proteoglycans in cancer, Lipid and atherosclerosis D09214 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
92 IL13 3件: JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Pathways in cancer D08857 Anrukinzumab 1件: 97
93 IL13 3件: JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Pathways in cancer D09633 Lebrikizumab 1件: 85
94 IL13 3件: JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Pathways in cancer D09979 Tralokinumab 2件: 85, 97
95 JAK1 17件: PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09959 Ruxolitinib 3件: 60, 65, 228
96 JAK1 17件: PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09970 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300
97 JAK1 17件: PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10308 Baricitinib 13件: 2, 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325
98 JAK1 17件: PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10653 Peficitinib 1件: 46
99 JAK1 17件: PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10871 Filgotinib 6件: 46, 53, 96, 97, 222, 271
100 JAK1 17件: PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10944 Itacitinib 4件: 46, 51, 97, 228
101 JAK1 17件: PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10994 Upadacitinib 8件: 40, 41, 46, 49, 96, 97, 107, 271
102 JAK1 17件: PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D11400 Abrocitinib 1件: 84
103 JAK2 14件: PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Prolactin signaling pathway, Leishmaniasis, Toxoplasmosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09959 Ruxolitinib 3件: 60, 65, 228
104 JAK2 14件: PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Prolactin signaling pathway, Leishmaniasis, Toxoplasmosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D09970 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300
105 JAK2 14件: PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Prolactin signaling pathway, Leishmaniasis, Toxoplasmosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D10308 Baricitinib 13件: 2, 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325
106 JAK2 14件: PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Prolactin signaling pathway, Leishmaniasis, Toxoplasmosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D10653 Peficitinib 1件: 46
107 JAK3 11件: PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer, Viral carcinogenesis, Non-small cell lung cancer, Primary immunodeficiency D09970 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300
108 JAK3 11件: PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer, Viral carcinogenesis, Non-small cell lung cancer, Primary immunodeficiency D10653 Peficitinib 1件: 46
109 LEPR 3件: Neuroactive ligand-receptor interaction, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease D05014 Metreleptin 1件: 265
110 MPL 1件: JAK-STAT signaling pathway D08990 Romiplostim 4件: 60, 63, 64, 65
111 MPL 1件: JAK-STAT signaling pathway D10306 Avatrombopag 2件: 60, 63
112 IL20 2件: Viral protein interaction with cytokine and cytokine receptor, JAK-STAT signaling pathway D11756 Fletikumab 1件: 46
113 IL22 2件: JAK-STAT signaling pathway, Th17 cell differentiation D11953 Efmarodocokin alfa 2件: 96, 97
114 IL23A 6件: JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Rheumatoid arthritis D09214 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
115 IL23A 6件: JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Rheumatoid arthritis D10400 Tildrakizumab 2件: 162, 271
116 IL23A 6件: JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Rheumatoid arthritis D10438 Guselkumab 5件: 37, 41, 51, 96, 97
117 IL23A 6件: JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Rheumatoid arthritis D10912 Brazikumab 2件: 96, 97
118 IL23A 6件: JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Rheumatoid arthritis D11052 Risankizumab 4件: 37, 96, 97, 271
119 IL23A 6件: JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Rheumatoid arthritis D11123 Mirikizumab 3件: 37, 96, 97
120 PDGFRA 11件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma D08066 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
121 PDGFRA 11件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma D08552 Sunitinib 2件: 28, 34
122 PDGFRA 11件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma D08953 Nilotinib 5件: 6, 8, 34, 51, 86
123 PDGFRA 11件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma D10481 Nintedanib 5件: 51, 85, 89, 227, 228
124 PDGFRB 11件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma D03658 Dasatinib 2件: 51, 85
125 PDGFRB 11件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma D06414 Dasatinib 2件: 51, 85
126 PDGFRB 11件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma D08524 Sorafenib 2件: 34, 86
127 PDGFRB 11件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma D08552 Sunitinib 2件: 28, 34
128 PDGFRB 11件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma D08953 Nilotinib 5件: 6, 8, 34, 51, 86
129 PDGFRB 11件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Melanoma D10481 Nintedanib 5件: 51, 85, 89, 227, 228
130 PIK3CA 50件: Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D11011 Alpelisib 1件: 138
131 PIK3CA 50件: Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D11158 Leniolisib 2件: 53, 65
132 PIK3CB 50件: Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D11158 Leniolisib 2件: 53, 65
133 PIK3CD 50件: Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D11158 Leniolisib 2件: 53, 65
134 PIK3CD 50件: Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Leukocyte transendothelial migration, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D11437 Parsaclisib 3件: 35, 53, 61
135 PRL 4件: Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway D00987 Cabergoline 3件: 6, 74, 75
136 PRL 4件: Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway D01348 Terguride 2件: 51, 86
137 PRL 4件: Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway D03165 Bromocriptine 2件: 6, 74
138 RAF1 39件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D08524 Sorafenib 2件: 34, 86
139 BCL2 22件: Platinum drug resistance, NF-kappa B signaling pathway, Sphingolipid signaling pathway, p53 signaling pathway, Protein processing in endoplasmic reticulum, PI3K-Akt signaling pathway, Necroptosis, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Neurotrophin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Shigellosis, Salmonella infection, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Small cell lung cancer, Lipid and atherosclerosis D10679 Venetoclax 1件: 28
140 TYK2 9件: Necroptosis, Osteoclast differentiation, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Measles, Kaposi sarcoma-associated herpesvirus infection D09970 Tofacitinib 15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300
141 TYK2 9件: Necroptosis, Osteoclast differentiation, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Measles, Kaposi sarcoma-associated herpesvirus infection D11817 Deucravacitinib 3件: 49, 96, 97
142 TSLP 1件: JAK-STAT signaling pathway D11771 Tezepelumab 1件: 98